News
IONS
76.82
+0.08%
0.06
Is It Time To Reassess Ionis Pharmaceuticals (IONS) After A 171% One Year Surge?
Simply Wall St · 8h ago
Ionis to webcast first-quarter financial results, program updates
PUBT · 1d ago
Press Release: Ionis to hold first quarter 2026 financial results webcast
Dow Jones · 1d ago
Ionis to hold first quarter 2026 financial results webcast
Barchart · 1d ago
What Ionis Pharmaceuticals (IONS)'s Renewed Analyst Focus on Tryngolza Means For Shareholders
Simply Wall St · 2d ago
Weekly Report: what happened at IONS last week (0406-0410)?
Weekly Report · 3d ago
Nike downgraded, IBM initiated: Wall Street’s top analyst calls
TipRanks · 5d ago
IONIS PHARMACEUTICALS INC <IONS.O>: RAYMOND JAMES RESUMES COVERAGE WITH OUTPERFORM RATING; TARGET PRICE $104
Reuters · 6d ago
Ionis Pharmaceuticals Is Maintained at Buy by B of A Securities
Dow Jones · 6d ago
Ionis Pharmaceuticals Price Target Raised to $111.00/Share From $100.00 by B of A Securities
Dow Jones · 6d ago
B of A Securities Maintains Buy on Ionis Pharmaceuticals, Raises Price Target to $111
Benzinga · 6d ago
Ionis Pharmaceuticals price target raised to $111 from $100 at BofA
TipRanks · 6d ago
IONIS PHARMACEUTICALS INC <IONS.O>: BOFA GLOBAL RESEARCH RAISES PRICE OBJECTIVE TO $111 FROM $100
Reuters · 6d ago
Analysts Are Bullish on These Healthcare Stocks: EDAP TMS (EDAP), Ionis Pharmaceuticals (IONS)
TipRanks · 6d ago
U.S. RESEARCH ROUNDUP-Comstock Resources, Trustmark, Viasat
Reuters · 04/09 07:50
Ionis Extends Donidalorsen Into Children: What the New HAE Trial Means for Investors
TipRanks · 04/07 16:31
Analysts Offer Insights on Healthcare Companies: Ionis Pharmaceuticals (IONS), Corbus Pharmaceuticals (CRBP) and Artivion (AORT)
TipRanks · 04/07 14:30
Rare Stock Picks In March 2026 - From 23 Discerning Analysts
Seeking Alpha · 04/06 12:00
Weekly Report: what happened at IONS last week (0330-0403)?
Weekly Report · 04/06 09:27
Will Priority FDA Review of Zilganersen and Tryngolza Pricing Shift Ionis Pharmaceuticals' (IONS) Narrative
Simply Wall St · 04/05 22:18
More
Webull provides a variety of real-time IONS stock news. You can receive the latest news about Ionis Pharmaceuticals through multiple platforms. This information may help you make smarter investment decisions.
About IONS
Ionis Pharmaceuticals, Inc. develops six marketed medicines for serious diseases, including medicines for neurologic and cardiovascular diseases. Its marketed medicines consist of TRYNGOLZA, WAINUA (eplontersen), SPINRAZA (nusinersen), QALSODY (tofersen), TEGSEDI (inotersen) and WAYLIVRA (volanesorsen). TRYNGOLZA reduces triglyceride levels in adults with familial chylomicronemia syndrome (FCS). WAINUA is approved for the treatment of the polyneuropathy of hereditary transthyretin-medicated amyloidosis (ATTRv-PN) in adults. SPINRAZA is used for the treatment of pediatric and adult patients with spinal muscular atrophy. QALSODY is approved for the treatment of Amyotrophic Lateral Sclerosis in adults who have a mutation in the superoxide dismutase 1 (SOD1) gene, or SOD1-ALS. TEGSEDI is approved for the treatment of ATTRv-PN in adults. WAYLIVRA is approved as an adjunct to diet in adult patients with genetically confirmed FCS and at high risk of acute, potentially fatal pancreatitis.